A study based on 44 NSCLC patients with high PD-L1 expression showed that patients with KRAS G12C mutations have a significantly longer PFS when treated with anti-PD-1 immunotherapy [68]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.